The CEO of a biotech platform technology company needed to assess the strategic fit of its technology in the complement inhibitor space.
MSC was engaged to gather competitive intelligence about inhibitors developed against characterized targets in the immunological cascade to identify development opportunities were the client would have a competitive edge. A shortlist of potential licensees was crafted based on identified drug candidates with technical disadvantages (e.g. short half-life, molecule size, cost of goods, etc.) that the client’s technology would be able to address. The CEO presented the outcome to his board and subsequently used it as a foundation for the company’s collaboration strategy in this space.